Integra LifeSciences has entered into an exclusive worldwide license and development agreement with Stout Medical Group to develop and commercialise an expandable interbody device.
The license allows Integra to develop a device that can be implanted by the surgeons into disc space using minimally invasive techniques.
The device will enable the surgeons to perform a potentially safer, simpler procedure.
During an interbody fusion procedure, the new technology will allow surgeons to adjust the height in-situ depending on the patient’s needs.
Integra Global Spine/Orthobiologics president and head of Strategic Development Brian Larkin said the expandable interbody fusion platform is an important and innovative addition to their minimally invasive device portfolio.
"This agreement leverages our considerable expertise in business development, and underscores our commitment to provide new technology to our spine distribution partners," Larkin said.